keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine cancer

keyword
https://www.readbyqxmd.com/read/29924681/identifying-and-understanding-the-gaps-in-care-experienced-by-adolescent-and-young-adult-cancer-patients-at-the-university-of-iowa-hospitals-and-clinics
#1
Erin M Mobley, Kristin J Foster, William W Terry
PURPOSE: In an effort to counteract the differences in improvement in survival rates of adolescents and young adults (AYA), compared to other age groups with cancer, the University of Iowa Hospitals and Clinics established an AYA cancer program. This study was conducted to gather feedback from AYAs in an effort to generate actionable data for program development. METHODS: The target population included patients aged 13-31 treated for malignancy in one of the following disease sites: central nervous system, leukemia, lymphoma, neuroendocrine, sarcoma, and thyroid...
June 20, 2018: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/29924023/small-cell-lung-cancer-mimicking-lymphoma-in-ct-and-68ga-dota-noc-pet-ct-a-case-report
#2
Liyan Lu, Fengfang Li, Yamei Zhang, Peng Wang, Xindao Yin, Wenbin Li
RATIONALE: Small cell lung cancer accounts for 15-20% of all lung cancers and is the most common pulmonary neuroendocrine neoplasm. Most small cell lung cancers arise from lobar or main bronchi, the most common manifestations of small cell lung cancer is a large mass centrally located within the lung parenchyma or a mediastinal mass involving the hilus. Small cell lung cancer is easily ignored by clinicians without lung parenchyma and hilus involvement. Here, we report a case of small cell lung cancer, which was misdiagnosed as the lymphoma in contrast enhanced CT and Ga-DOTA-NOC PET/CT imagings...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29921838/patient-derived-organoids-to-model-rare-prostate-cancer-phenotypes
#3
Loredana Puca, Rohan Bareja, Davide Prandi, Reid Shaw, Matteo Benelli, Wouter R Karthaus, Judy Hess, Michael Sigouros, Adam Donoghue, Myriam Kossai, Dong Gao, Joanna Cyrta, Verena Sailer, Aram Vosoughi, Chantal Pauli, Yelena Churakova, Cynthia Cheung, Lesa Dayal Deonarine, Terra J McNary, Rachele Rosati, Scott T Tagawa, David M Nanus, Juan Miguel Mosquera, Charles L Sawyers, Yu Chen, Giorgio Inghirami, Rema A Rao, Carla Grandori, Olivier Elemento, Andrea Sboner, Francesca Demichelis, Mark A Rubin, Himisha Beltran
A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of prostate cancer that may arise de novo or as a mechanism of treatment resistance in patients with pre-existing castration-resistant prostate cancer. There are few available models to study neuroendocrine prostate cancer. Here, we report the generation and characterization of tumor organoids derived from needle biopsies of metastatic lesions from four patients...
June 19, 2018: Nature Communications
https://www.readbyqxmd.com/read/29921690/neoadjuvant-intensive-androgen-deprivation-therapy-selects-for-prostate-tumor-foci-with-diverse-subclonal-oncogenic-alterations
#4
Adam G Sowalsky, Huihui Ye, Manoj Bhasin, Eliezer M Van Allen, Massimo Loda, Rosina T Lis, Laleh Montaser-Kouhsari, Carla Calagua, Fen Ma, Joshua W Russo, Rachel J Schaefer, Olga S Voznesensky, Zhenwei Zhang, Glenn J Bubley, Bruce Montgomery, Elahe A Mostaghel, Peter S Nelson, Mary-Ellen Taplin, Steven P Balk
Primary prostate cancer (PCa) can have extensive microheterogeneity, but its contribution to the later emergence of metastatic castration-resistant PCa (mCRPC) remains unclear. In this study, we microdissected residual PCa foci in radical prostatectomies from 18 men treated with neoadjuvant intensive androgen deprivation therapy (leuprolide, abiraterone acetate, and prednisone) and analyzed them for resistance mechanisms. Transcriptome profiling showed reduced but persistent androgen receptor (AR) activity in residual tumors with no increase in neuroendocrine differentiation...
June 19, 2018: Cancer Research
https://www.readbyqxmd.com/read/29914531/mgmt-promoter-methylation-and-1p-19q-co-deletion-of-surgically-resected-pulmonary-carcinoid-and-large-cell-neuroendocrine-carcinoma
#5
Lei Lei, Zhiming Jiang, Gu Zhang, Qiaoyuan Cheng, Hongyang Lu
BACKGROUND: The response to temozolomide (TMZ) treatment in small-cell lung cancer (SCLC) correlated with O(6)-methylguanine -DNA methyltransferase (MGMT) promoter methylation. 1p/19q co-deletion within oligodendroglioma is a responsive predictor for TMZ. Currently, the status of MGMT promoter methylation and 1p/19q co-deletion in pulmonary carcinoid (PC) and large-cell neuroendocrine carcinoma (LCNEC) is not reported. METHODS: Nine PC [two atypical carcinoids (AC), seven typical carcinoids (TC)] and six LCNEC patients were collected retrospectively...
June 18, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29911510/mixed-adenoneuroendocrine-carcinoma-of-the-colon-and-rectum
#6
S Qiu, G Pellino, O J Warren, S Mills, R Goldin, C Kontovounisios, P P Tekkis
Mixed adenoneuroendocrine carcinoma (MANEC) are rare cancers of the gastrointestinal (GI) and pancreatobiliary tract. They are characterized by the presence of a combination of epithelial and neuroendocrine elements, where each component represents at least 30% of the tumour. Review of literature and consolidation of clinicopathological data. Sixty-one cases of colorectal MANEC have been reported in literature and one seen in this centre. The median age of the patients affected was 61.9 ± 12.4 years (20-94 years)...
June 17, 2018: Acta Chirurgica Belgica
https://www.readbyqxmd.com/read/29909903/systemic-therapy-in-non-conventional-cancers-of-the-larynx
#7
REVIEW
Elaine Tan, Mayur D Mody, Nabil F Saba
Laryngeal cancer (LC) remains a challenging disease to treat. The majority of LCs diagnosed worldwide are squamous cell carcinomas (SCC), and current treatment guidelines are designed to address conventional laryngeal SCC. However, several histologically rare tumor types can originate in the larynx. There is a lack of guidelines regarding the best therapeutic approaches to these tumors and their treatment is often modeled after their recommended management at non-laryngeal sites. Understanding the role for systemic therapy in these rare tumors is important, especially for patients with advanced disease or those who are not surgical candidates...
July 2018: Oral Oncology
https://www.readbyqxmd.com/read/29905005/targeting-mct4-to-reduce-lactic-acid-secretion-and-glycolysis-for-treatment-of-neuroendocrine-prostate-cancer
#8
Stephen Yiu Chuen Choi, Susan L Ettinger, Dong Lin, Hui Xue, Xinpei Ci, Noushin Nabavi, Robert H Bell, Fan Mo, Peter W Gout, Neil E Fleshner, Martin E Gleave, Colin C Collins, Yuzhuo Wang
Development of neuroendocrine prostate cancer (NEPC) is emerging as a major problem in clinical management of advanced prostate cancer (PCa). As increasingly potent androgen receptor (AR)-targeting antiandrogens are more widely used, PCa transdifferentiation into AR-independent NEPC as a mechanism of treatment resistance becomes more common and precarious, since NEPC is a lethal PCa subtype urgently requiring effective therapy. Reprogrammed glucose metabolism of cancers, that is elevated aerobic glycolysis involving increased lactic acid production/secretion, plays a key role in multiple cancer-promoting processes and has been implicated in therapeutics development...
June 14, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29904310/dramatic-response-to-cyclin-d-dependent-kinase-4-6-inhibitor-in-refractory-poorly-differentiated-neuroendocrine-carcinoma-of-the-breast
#9
Allison Shanks, Julia Choi, Vinit Karur
Neuroendocrine tumors are a rare subset of breast carcinomas. Commonly, platinum-based doublet is used as a systemic treatment option for high-grade neuroendocrine carcinomas from lung, gastrointestinal, and genitourinary origins. In comparison to other breast cancers, neuroendocrine carcinomas have unique genomic features and different treatment strategies. We present a patient with high-grade neuroendocrine carcinoma of the breast who had a successful and durable response to the cyclin D-dependent kinase (CDK) 4/6 inhibitor palbociclib in conjunction with endocrine therapy...
July 2018: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/29903510/quality-of-life-in-multiple-endocrine-neoplasia-type-2a-compared-with-normative-and-disease-populations
#10
Michael N Mongelli, Benjamin J Peipert, Sneha Goswami, Irene Helenowski, Susan E Yount, Cord Sturgeon
BACKGROUND: Patient-reported outcomes are measured in chronic disease states to inform intervention and management decisions while minimizing negative outcomes. We hypothesized that health-related quality of life in patients with multiple endocrine neoplasia type 2A would be worse than the general US population but similar to other chronic diseases. METHODS: Adults ≥18 years with multiple endocrine neoplasia type 2A were recruited to complete the Patient-Reported Outcomes Measurement Information System 29-item questionnaire (n = 45)...
June 11, 2018: Surgery
https://www.readbyqxmd.com/read/29900476/mixed-adenoneuroendocrine-carcinoma-of-the-esophagogastric-junction-a-case-report
#11
Miho Yamamoto, Soji Ozawa, Kazuo Koyanagi, Junya Oguma, Akihito Kazuno, Yamato Ninomiya, Kentaro Yatabe, Kazuhito Hatanaka
BACKGROUND: Mixed adenoneuroendocrine carcinoma (MANEC) is a tumor of the gastrointestinal tract that contains both exocrine and endocrine components, with each component exceeding 30% of the total tumor area. Because MANECs are exceedingly rare, no therapeutic strategies have been established yet. CASE PRESENTATION: An 81-year-old man was referred to our hospital with a 5-month history of dysphagia. Esophagogastroduodenoscopy revealed an ulcerated mass in the lower thoracic esophagus, extending up to the esophagogastric junction (33 to 40 cm from the incisors)...
June 14, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29899320/pancreatic-cystic-lesions-pathogenesis-and-malignant-potential
#12
REVIEW
Antoinette J Pusateri, Somashekar G Krishna
Pancreatic cancer remains one of the most lethal cancers despite extensive research. Further understanding of precursor lesions may enhance the ability to treat and prevent pancreatic cancer. Pancreatic cystic lesions (PCLs) with malignant potential include: mucinous PCLs (intraductal papillary mucinous neoplasms and mucinous cystic neoplasm), solid pseudopapillary tumors and cystic neuroendocrine tumors. This review summarizes the latest literature describing what is known about the pathogenesis and malignant potential of these PCLs, including unique epidemiological, radiological, histological, genetic and molecular characteristics...
June 13, 2018: Diseases (Basel)
https://www.readbyqxmd.com/read/29898448/pro-gastrin-releasing-peptide-a-new-serum-marker-for-endometrioid-adenocarcinoma
#13
Mine Kiseli, Gamze Sinem Caglar, Asli Yarci Gursoy, Tolga Tasci, Tuba Candar, Egemen Akincioglu, Emre Goksan Pabuccu, Nurettin Boran, Gokhan Tulunay, Haldun Umudum
BACKGROUND: Gastrin-releasing peptide (GRP) is thought to play a role in the metastatic process of various malignancies. The more stable precursor of GRP, pro-GRP (ProGRP), has been shown to be secreted by neuroendocrine tumors. This study was designed to assess the validity of ProGRP as a diagnostic marker in endometrioid adenocarcinomas (EAs) of the endometrium. METHODS: Thirty-seven patients with a diagnosis of EA, 23 patients with endometrial hyperplasia, and 32 age-matched controls with normal endometrial histology were recruited for this study...
June 13, 2018: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/29897580/recent-topics-around-multiple-endocrine-neoplasia-type-1
#14
Stephen J Marx
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is complex with regard to clinical expressions, management, and molecular pathways. Advances are being made broadly and in focused aspects. Selected topics are presented for their developments since publication of the most recent MEN1 consensus guidelines 6 years ago. Methods: Topics were selected for clinical impact or broad interest or both. For each topic, information was obtained from original reports and reviews...
April 1, 2018: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29892571/a-testosterone-metabolite-19-hydroxyandrostenedione-induces-neuroendocrine-trans-differentiation-of-prostate-cancer-cells-via-an-ectopic-olfactory-receptor
#15
Tatjana Abaffy, James R Bain, Michael J Muehlbauer, Ivan Spasojevic, Shweta Lodha, Elisa Bruguera, Sara K O'Neal, So Young Kim, Hiroaki Matsunami
Olfactory receptor OR51E2, also known as a Prostate Specific G-Protein Receptor, is highly expressed in prostate cancer but its function is not well understood. Through in silico and in vitro analyses, we identified 24 agonists and 1 antagonist for this receptor. We detected that agonist 19-hydroxyandrostenedione, a product of the aromatase reaction, is endogenously produced upon receptor activation. We characterized the effects of receptor activation on metabolism using a prostate cancer cell line and demonstrated decreased intracellular anabolic signals and cell viability, induction of cell cycle arrest, and increased expression of neuronal markers...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29891528/advances-in-immunotherapy-for-metastatic-merkel-cell-carcinoma-a-clinician-s-guide
#16
REVIEW
Kelly G Paulson, Shailender Bhatia
Merkel cell carcinoma (MCC) is a neuroendocrine skin cancer. The clinical impact of MCC has been increasing due to steadily rising incidence rates. Since 2001, more than 24,000 cases of MCC have been reported to the US National Program of Cancer Registries database, and in 2018, more than 2,500 incident cases are expected. MCC is highly aggressive, and one-third of patients will either present with or develop metastatic disease. Outcomes in patients with metastatic MCC have historically been poor; median time to progression with cytotoxic chemotherapy is only 3 months...
June 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29890952/modifier-locus-mapping-of-a-transgenic-f2-mouse-population-identifies-ccdc115-as-a-novel-aggressive-prostate-cancer-modifier-gene-in-humans
#17
Jean M Winter, Natasha L Curry, Derek M Gildea, Kendra A Williams, Minnkyong Lee, Ying Hu, Nigel P S Crawford
BACKGROUND: It is well known that development of prostate cancer (PC) can be attributed to somatic mutations of the genome, acquired within proto-oncogenes or tumor-suppressor genes. What is less well understood is how germline variation contributes to disease aggressiveness in PC patients. To map germline modifiers of aggressive neuroendocrine PC, we generated a genetically diverse F2 intercross population using the transgenic TRAMP mouse model and the wild-derived WSB/EiJ (WSB) strain...
June 11, 2018: BMC Genomics
https://www.readbyqxmd.com/read/29888431/differential-proteomic-analysis-between-small-cell-lung-carcinoma-sclc-and-pulmonary-carcinoid-tumors-reveals-molecular-signatures-for-malignancy-in-lung-cancer
#18
Kiyonaga Fujii, Yuka Miyata, Ikuya Takahashi, Hirotaka Koizumi, Hisashi Saji, Masahiro Hoshikawa, Masayuki Takagi, Toshihide Nishimura, Haruhiko Nakamura
PURPOSE: The molecular underpinnings that may prognosticate survival and increase our understanding of tumor development and progression are still poorly understood. This study aimed to define the molecular signatures for malignancy in small cell lung carcinoma (SCLC), which is known for its highly aggressive clinical features and poor prognosis. EXPERIMENTAL DESIGN: Using clinical specimens, we performed a comparative proteomic analysis of high-grade SCLCs and low-grade pulmonary carcinoid tumors (PCTs), both of which are types of neuroendocrine tumors...
June 11, 2018: Proteomics. Clinical Applications
https://www.readbyqxmd.com/read/29886587/-histologic-subtyping-of-poorly-differentiated-solid-lung-cancer-with-molecular-testing-for-epidermal-growth-factor-receptor-mutation-and-alk-gene-rearrangement-an-analyses-of-167-cases
#19
F Fang, Y X Wang, S T Hu, L Yang, J Di, D G Liu, N Lyu
Objective: To study the histological subtyping of poorly differentiated solid lung cancer by using immunohistochemistry and mucin staining along with analysis of epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) gene rearrangement. Methods: Among 827 cases of non-small cell lung cancer at Beijing Hospital from April 2014 to April 2017, 167 cases of solid poorly differentiated lung cancer were identified and histopathologically subtyped by mucin staining (D-PAS) and immunohistochemistry using 10 antibodies (CK7, vimentin, Ki-67, CK5/6, p40, TTF1, Napsin A, CD56, chromogranin A, and synaptophysin)...
June 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29878866/health-related-quality-of-life-in-patients-with-progressive-midgut-neuroendocrine-tumors-treated-with-177-lu-dotatate-in-the-phase-iii-netter-1-trial
#20
Jonathan Strosberg, Edward Wolin, Beth Chasen, Matthew Kulke, David Bushnell, Martyn Caplin, Richard P Baum, Pamela Kunz, Timothy Hobday, Andrew Hendifar, Kjell Oberg, Maribel Lopera Sierra, Thomas Thevenet, Ines Margalet, Philippe Ruszniewski, Eric Krenning
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of 177 Lu-Dotatate treatment on time to deterioration in health-related QoL. Methods The NETTER-1 trial is an international phase III study in patients with midgut NETs. Patients were randomly assigned to treatment with 177 Lu-Dotatate versus high-dose octreotide. European Organisation for Research and Treatment of Cancer quality-of-life questionnaires QLQ C-30 and G.I.NET-21 were assessed during the trial to determine the impact of treatment on health-related QoL...
June 7, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
44160
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"